 |
Joint Medicines Formulary |
 |
Airedale NHS Foundation Trust
Airedale, Wharfedale and Craven CCG |
|
| Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
|
Notes:
Unless explicitly stated, any brand names included in brackets next to a drug's generic name are there solely to aid searching and identification, and should not be considered to limit use to that specific brand. |
| Useful Links |
 DSU: Medicines with teratogenic potential: what is effective contraception and how often is pregnancy testing needed? (March 2019) |
|
Haematology and Oncology Protocols and Guidelines |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
08.01 |
Cytotoxic drugs (0,0)
|
|
|
Side-effects of cytotoxic drugs (0,0)
|
|
|
Drugs for cytotoxic-induced side-effects
(3,0)
|
|
08.01.01 |
Alkylating drugs
(4,0)
|
|
08.01.02 |
Anthracyclines and other cytotoxic antibiotics
(6,0)
|
|
08.01.03 |
Antimetabolites
(11,0)
|
|
08.01.04 |
Vinca alkaloids and etoposide
(4,0)
|
|
08.01.05 |
Other antineoplastic drugs
(19,0)
|
|
|
Amsacrine (0,0)
|
|
|
Arsenic trioxide (0,0)
|
|
|
Bevacizumab
(1,0)
|
|
|
Bexarotene (0,0)
|
|
|
Bortezomib
(3,0)
|
|
|
Cetuximab
(1,0)
|
|
|
Crisantaspase (0,0)
|
|
|
Dacarbazine and Temozolomide
(1,0)
|
|
|
Hydroxycarbamide
(1,0)
|
|
|
Ipilimumab (0,0)
|
|
|
Mitotane (0,0)
|
|
|
Panitumumab
(1,0)
|
|
|
Pentostatin (0,0)
|
|
|
Platinum compounds
(3,0)
|
|
|
Porfimer sodium and temoporfin (0,0)
|
|
|
Procarbazine
(1,0)
|
|
|
Protein kinase inhibitors
(18,0)
|
|
|
Taxanes
(3,0)
|
|
|
Topoisomerase I inhibitors
(2,0)
|
|
|
Trabectedin (0,0)
|
|
|
Trastuzumab
(2,0)
|
|
|
Tretinoin (0,0)
|
|
08.02 |
Drugs affecting the immune response (0,0)
|
|
|
Immunosuppressant therapy (0,0)
|
|
08.02.01 |
Antiproliferative immunosuppressants
(2,0)
|
|
08.02.02 |
Corticosteroids and other immunosuppressants
(2,0)
|
|
08.02.03 |
Rituximab and alemtuzumab
(3,0)
|
|
08.02.04 |
Other immunomodulating drugs
(5,0)
|
|
|
Interferon Alfa
(2,0)
|
|
|
Interferon beta (0,0)
|
|
|
Aldesleukin (0,0)
|
|
|
Glatiramer acetate (0,0)
|
|
|
Natalizumab (0,0)
|
|
08.03 |
Sex hormones and hormone antagonists in malignant disease (0,0)
|
|
08.03.01 |
Oestrogens
(2,0)
|
|
08.03.02 |
Progestogens
(2,0)
|
|
08.03.03 |
Androgens (0,0)
|
|
08.03.04 |
Hormone antagonists (0,0)
|
|
08.03.04.01 |
Breast cancer
(5,0)
|
|
08.03.04.02 |
Prostate cancer and gonadorelin analogues
(1,0)
|
|
|
Gonadorelin analogues (0,0)
|
|
|
Anti-androgens
(6,0)
|
|
08.03.04.03 |
Somatostatin analogues
(2,0)
|
|
|
|
